X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.fiercebiotech.com/biotech/astrazenecas-novel-checkpoint-inhibitor-flunks-first-phase-3-denting-partners-share-price
https://www.biospace.com/article/releases/monalizumab-data-from-coast-trial-presented-at-esmo-congress-2021/?s=71
https://www.fool.com/investing/2021/09/17/heres-why-innate-pharma-stock-is-rocketing-higher/
http://www.innate-pharma.com/en/news-events/press-releases/innate-pharma-present-additional-efficacy-data-monalizumab-combination-cetuximab-head-and-neck-cancer-esmo-immuno-oncology-virtual-congress
https://www.globenewswire.com/news-release/2020/05/14/2033189/0/en/Innate-Pharma-to-Present-New-Efficacy-Data-For-Monalizumab-in-Combination-With-Cetuximab-in-Head-And-Neck-cancer-at-The-ASCO20-Virtual-Scientific-Progral.html
https://www.clinicaltrialsarena.com/news/innate-pharma-monalizumab-phaseiii/
http://www.pmlive.com/pharma_news/innate_pharma_and_astrazeneca_take_monalizumab_into_phase_3_1302699
https://www.reuters.com/article/us-astrazeneca-innate-pharma/astrazeneca-digs-deeper-into-cancer-with-innate-stake-idUSKCN1MX0FK
Market Place
Share 
